Immunovant Inc [IMVT] stock is trading at $15.47, up 0.23%. An important factor to consider is whether the stock is rising or falling in short-term value. The IMVT shares have gain 16.19% over the last week, with a monthly amount drifted -22.75%, and not seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Immunovant Inc [NASDAQ: IMVT] stock has seen the most recent analyst activity on March 03, 2025, when Jefferies initiated its Hold rating and assigned the stock a price target of $20. Previously, Wolfe Research downgraded its rating to Peer Perform on January 03, 2025. Oppenheimer reiterated its Outperform rating and increased its price target to $53 on October 09, 2024. Oppenheimer initiated its recommendation with a Outperform and recommended $50 as its price target on March 28, 2024. Goldman started tracking with a Buy rating for this stock on March 13, 2024, and assigned it a price target of $50. In a note dated February 20, 2024, JP Morgan initiated an Overweight rating and provided a target price of $51 on this stock.
Immunovant Inc [IMVT] stock has fluctuated between $12.72 and $34.47 over the past year. Currently, Wall Street analysts expect the stock to reach $42.83 within the next 12 months. Immunovant Inc [NASDAQ: IMVT] shares were valued at $15.47 at the most recent close of the market. An investor can expect a potential return of 176.86% based on the average IMVT price forecast.
Analyzing the IMVT fundamentals
Gross Profit Margin for this corporation currently stands at 0.9% with Operating Profit Margin at -270.14%, Pretax Profit Margin comes in at -254.78%, and Net Profit Margin reading is -255.14%. To continue investigating profitability, this company’s Return on Assets is posted at -0.91, Equity is -0.78 and Total Capital is -1.15. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at 0.0.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 15.20 points at the first support level, and at 14.94 for the second support level. However, for the 1st resistance point, the stock is sitting at 15.74, and for the 2nd resistance point, it is at 16.02.
Ratios To Look Out For
For context, Immunovant Inc’s Current Ratio is 6.04. On the other hand, the Quick Ratio is 6.04, and the Cash Ratio is 5.48.
Transactions by insiders
Recent insider trading involved Salzmann Peter, Chief Executive Officer, that happened on Apr 09 ’25 when 28094.0 shares were sold. Director, Fromkin Andrew J. completed a deal on Mar 07 ’25 to sell 8000.0 shares. Meanwhile, Director ANDREW J FROMKIN bought 8000.0 shares on Mar 07 ’25.
